Results 241 to 250 of about 56,984,652 (272)

Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis

Journal of the American Academy of Dermatology, 2014
Interleukin (IL)-31 induces severe pruritus and dermatitis in transgenic mice, and is associated with many itching skin diseases.We sought to investigate the association of serum IL-31 levels with uremic pruritus in patients undergoing hemodialysis.Patients receiving maintenance hemodialysis in a referral medical center were recruited.
Mei-Ju, Ko, Yu-Sen, Peng, Hung-Yuan, Chen, Shih-Ping, Hsu, Mei-Fen, Pai, Ju-Yeh, Yang, Su-Ying, Wen, Shiou-Hwa, Jee, Hon-Yen, Wu, Hsien-Ching, Chiu   +9 more
openaire   +2 more sources

Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis

Current Treatment Options in Allergy, 2018
Atopic dermatitis (AD) is a chronic eczematous skin disease associated with intense pruritus and skin barrier dysfunction. Interleukin-31 (IL-31), which is preferentially produced by T helper 2 (Th2) cells, has attracted attention as a pruritogen in patients with AD.
Takeshi Nakahara, Masutaka Furue
openaire   +1 more source

Immunohistochemical study of interleukin-31 in patients with atopic dermatitis

Egyptian Journal of Dermatology and Venereology, 2018
Background Atopic dermatitis (AD) is a common chronic inflammatory skin disease of unknown etiology. Reduction of pruritus as one of the hallmarks of AD is the most effective therapeutic strategy for improving quality of life and for preventing aggravation of skin lesion. Interleukin-31 (IL-31) has been suggested to play a role
Tarek E. Amin, Nashwa N. Elfar, Fersan A. Sallam   +2 more
openaire   +1 more source

Targeting Interleukin-31 in Prurigo

New England Journal of Medicine, 2023
openaire   +2 more sources

A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis

Inflammopharmacology
Prurigo nodularis (PN) is a neuroimmunological skin disease. Severe itching is the most challenging symptom which affects patients' quality of life. T helper 2-derived cytokines, such as interleukin-31 and oncostatin M (OSM), play a crucial role in PN pathogenesis. Nemolizumab and vixarelimab are two biologics acting as IL-31 inhibitors.
Mohammad Ali Nilforoushzadeh, Nazila Heidari, Yekta Ghane, Amirhossein Heidari, Arman Hajikarim-Hamedani, SeyedAyin Hosseini, Fariba Jaffary, Minou Najar Nobari, Pegah Tavakolzadeh, Niloufar Najar Nobari   +9 more
openaire   +2 more sources

The role of interleukin-31 in human allergic disease

2012
The newly described cytokine Interleukin (IL) 31 has been shown to be expressed by murine activated T lymphocytes of a Th2 phenotype. Like IL-17 and IL-22, IL-31 is a tissue signalling cytokine whose receptor is mainly found on non-immune cells.
openaire   +2 more sources

Interleukins in cancer: from biology to therapy

Nature Reviews Cancer, 2021
Peter Libby, Daria Briukhovetska, Stefan Endres   +2 more
exaly  

gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES

Annual Review of Immunology, 1997
Tadamitsu Kishimoto, Tetsuya Taga
exaly  

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Nature Reviews Drug Discovery, 2012
Charles A. Dinarello, Anna Simon
exaly  

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis

European Heart Journal, 2020
Tom Thuren, Peter Libby
exaly